Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
TypePublic
HQCrestwood, US
Founded2008
Size (employees)32 (est)
Websiteapellis.com
Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Apellis Pharmaceuticals

Cedric Francois

Cedric Francois

President and CEO
Mike Yeadon

Mike Yeadon

Chief Scientific Officer
Pascal Deschatelets

Pascal Deschatelets

Founder & Chief Operating Officer
Show more

Apellis Pharmaceuticals Office Locations

Apellis Pharmaceuticals has offices in Waltham, Cambridge, San Francisco and Crestwood
Crestwood, US (HQ)
6400 Westwind Way
Cambridge, US
1218 Massachusetts Ave
San Francisco, US
300 41 Grant Ave
Waltham, US
200 5th Ave
Show all (4)
Report incorrect company information

Apellis Pharmaceuticals Financials and Metrics

Apellis Pharmaceuticals Revenue

USD

EBIT (Q2, 2018)

(54.9 m)

Market capitalization (21-Sep-2018)

1.1 b

Closing stock price (21-Sep-2018)

19.9

Cash (30-Jun-2018)

253.8 m
Apellis Pharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2017

Cash

175.6 m

Current Assets

182 m

Total Assets

182.1 m

Accounts Payable

3.7 m
Quarterly
USDQ1, 2018Q2, 2018

Cash

152.9 m253.8 m

Current Assets

163.1 m266.7 m

Total Assets

163.2 m266.8 m

Accounts Payable

4.6 m5.1 m
Annual
USDFY, 2017

Net Income

(51 m)

Accounts Payable

932.3 k

Cash From Operating Activities

(46.6 m)

Cash From Financing Activities

197.4 m
Quarterly
USDQ1, 2018Q2, 2018

Net Income

(21.7 m)(55.1 m)

Accounts Payable

921.8 k1.5 m

Cash From Operating Activities

(22.9 m)(53.6 m)

Cash From Financing Activities

222.7 k131.8 m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Apellis Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Apellis Pharmaceuticals News and Updates

Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy

PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™

Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results

- Commenced Phase 3 Trial of APL-2 in Paroxysmal Nocturnal Hemoglobinuria (PNH); APL-2 in Geographic Atrophy (GA) Remains On Track to Advance into Phase 3 in 2H18 -
Report incorrect company information

Apellis Pharmaceuticals Company Life and Culture

Report incorrect company information